Roivant

Roivant is a prominent tech-enabled healthcare company founded in 2014, specializing in biopharmaceutical development and innovative healthcare technology. The firm leverages advanced machine learning, computational science, and data-driven analytics to accelerate drug discovery and complete the development of promising late-stage drug candidates. Operating under the ticker NASDAQ: ROIV, the company focuses on delivering novel medical solutions to patients through an end-to-end R&D model that bridges the gap between scientific research and commercial-stage application.

The organization maintains a robust operational footprint with 7 distinct locations globally. Learn about Roivant's global headquarters for detailed geographic information regarding their primary operations in New York and their international presence. With a dedicated workforce of 500-1,000 employees, Roivant integrates diverse technical expertise across software engineering, medical research, and general management to drive its complex biopharmaceutical pipeline. This multidisciplinary approach ensures that the company remains agile in addressing unmet medical needs while maintaining high standards of operational efficiency.

Roivant competes with industry leaders such as Verily, Moderna, and Alnylam Pharmaceuticals within the highly competitive healthcare services sector. The company has secured significant private equity funding throughout its history, including a notable $1.1B round in 2017 and a $200.0M investment in 2018. Meet Roivant's team to explore their leadership structure and organizational culture, or Explore financial highlights to review their current revenue of $7.5M and broader financial performance metrics. These strategic investments support their ongoing commitment to transforming the pharmaceutical landscape through technology.